Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
15
NCT02869243
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 18, 2017
Completion: Jun 30, 2021